[Breaking] AmedBio to Receive ODS025 Milestone Payment from Boehringer Ingelheim, Equivalent to Over 10% of Last Year's Operating Revenue
AmedBio announced in a regulatory filing on the 26th that it is set to receive a milestone technology fee under its ODS025 technology transfer agreement with Germany's Boehringer Ingelheim International GmbH. According to the company, the claimed milestone payment amounts to more than 10% of its op
![[Breaking] AmedBio to Receive ODS025 Milestone Payment from Boehringer Ingelheim, Equivalent to Over 10% of Last Year's Operating Revenue](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F579545%2F36de0fb87055dd02%2Foriginal.webp&w=1920&q=75)
AmedBio announced in a regulatory filing on the 26th that it is set to receive a milestone technology fee under its ODS025 technology transfer agreement with Germany's Boehringer Ingelheim International GmbH.
According to the company, the claimed milestone payment amounts to more than 10% of its operating revenue (approximately 47.3 billion won) based on its 2025 consolidated financial statements. The specific amount to be received has not been disclosed due to confidentiality clauses in the contract.
AmedBio received written notification of the milestone achievement from its contract counterparty on the 26th, and the technology fee is expected to be received within 45 days of the counterparty's receipt of the invoice.
The technology transfer agreement was signed on October 15, 2025, before AmedBio's listing on the KOSDAQ market. The company explained that, as the contract was signed prior to its listing, there was no separate disclosure regarding the contract's execution.
According to the filing, the technology transfer agreement may be terminated if future clinical trials, approvals, or commercialization do not materialize. However, even if the contract is terminated, AmedBio has no obligation to return the milestone technology fees.
The company will withhold disclosure of monetary information, including the milestone payment amount, until the contract's termination date, in accordance with the confidentiality clauses. If key contract terms change in the future or disclosure obligations arise, the company plans to make disclosures without delay.
Meanwhile, AmedBio also filed a major management matter on June 26 regarding the receipt of a milestone technology fee under the ODS025 technology transfer agreement.
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] Cyberattack via Optimizely Exposes 178 Global Organizations... CNN, BBC, HSBC, and Ledger Also Affected](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F627874%2Ffc472b72a2596aa1%2Fvariants%2Fhero.webp&w=1920&q=75)


